Market Place
Sourcing Support
LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq
05 Jan 2024 //
GLOBENEWSWIRE
Roche to buy part of LumiraDx diagnostics platform for $295 million
29 Dec 2023 //
REUTERS
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
27 Oct 2023 //
GLOBENEWSWIRE
LumiraDx Partners with AstraZeneca & Everton
20 Oct 2023 //
GLOBENEWSWIRE
LumiraDx Reports Second Quarter 2023 Results
24 Aug 2023 //
GLOBENEWSWIRE
LumiraDx to Announce Second Quarter Financial Results
16 Aug 2023 //
GLOBENEWSWIRE
LumiraDx`s Point of Care Diagnostics Group Continues Commercial Expansion
31 Jul 2023 //
GLOBENEWSWIRE
LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
30 Jun 2023 //
GLOBENEWSWIRE
LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
20 Jun 2023 //
GLOBENEWSWIRE
LumiraDx Reports First Quarter 2023 Results
16 May 2023 //
GLOBENEWSWIRE
LumiraDx to Announce 1Q FYR and Host Quarterly Conference Call on May 16
09 May 2023 //
GLOBENEWSWIRE
LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
24 Apr 2023 //
GLOBENEWSWIRE
LumiraDx Announces Strategic Refocus and Cost Restructuring Program
06 Apr 2023 //
GLOBENEWSWIRE
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
21 Mar 2023 //
GLOBENEWSWIRE
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results
14 Mar 2023 //
GLOBENEWSWIRE
LumiraDx to Present at Raymond James Institutional Investors Conference
03 Mar 2023 //
GLOBENEWSWIRE
LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements
17 Feb 2023 //
GLOBENEWSWIRE
LumiraDx Receives FDA Emergency Use Authorization for Influenza Molecular Assay
06 Feb 2023 //
GLOBENEWSWIRE
LumiraDx Announces Nasdaq Notification Letter Regarding Bid Price Deficiency
31 Jan 2023 //
GLOBENEWSWIRE
LumiraDx Announces Commercial Shipment of Point of Care NT-proBNP Test in Europe
31 Jan 2023 //
GLOBENEWSWIRE
LumiraDx Announces New Investment for Development of Molecular Tuberculosis Test
14 Dec 2022 //
GLOBENEWSWIRE
LumiraDx Continues Commercial Expansion of Microfluidic HbA1c Test
14 Nov 2022 //
GLOBENEWSWIRE
LumiraDx to Announce Third Quarter Financial Results
02 Nov 2022 //
GLOBENEWSWIRE
LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation
12 Oct 2022 //
GLOBENEWSWIRE
LumiraDx Partners with British In Vitro Diagnostics Association
23 Sep 2022 //
PHARMATIMES
LumiraDx Partners with British In Vitro Diagnostics Association to Report
22 Sep 2022 //
GLOBENEWSWIRE
LumiraDx Reports Second Quarter 2022 Results
18 Aug 2022 //
GLOBENEWSWIRE
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly
11 Aug 2022 //
GLOBENEWSWIRE
LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira
09 Jun 2022 //
PRNEWSWIRE
UK MHRA approves LumiraDx Covid-19 molecular assay, SARS-CoV-2 RNA STAR
22 Feb 2022 //
PHARMABIZ
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects Omicron Variant
14 Jan 2022 //
PRNEWSWIRE
LumiraDx’s SARS-CoV-2 & Flu A/B Antigen Test receives CE marking
24 Dec 2021 //
PHARMABIZ
LumiraDx receives approval for its COVID-19 Antigen Test for use in India
20 Oct 2021 //
BIOSPACE
